Prostate cancer remains one of the most common cancers and is among the most lethal in men worldwide. It is significant that prostate cancer is identified in the early stages as the disease can be highly metastatic leading to a low survival rate. Therefore, it is essential for patients to have a better prognosis and able to be treated early. The diagnostic tools to identify prostate cancer have developed throughout the years which includes but is not limited to transrectal ultrasound-guided prostate biopsy and histopathology prior to radical prostatectomy. However, biopsies have been found to be invasive in addition to studies demonstrating an underdiagnosis of patients who have advanced prostate cancer.
Other diagnostic tools for prostate cancer include but are not limited to: pathological digital rectal examination (DRE), prostate specific antigen (PSA) and magnetic resonance image (MRI). These techniques are utilized to improve the detection of advanced prostate cancer in addition to reducing the invasive approach of biopsies. Addition to the current diagnostic tools, there is a development in 18F-fluoride (NaF) positron emission tomography/computed tomography (PET/CT) and 18F-fluorocholine (FCH) PET/CT, and whole-body magnetic resonance imaging (WBMRI) which has been proposed to detect prostate cancer metastasis. Studies have shown multi-parametric MRI has increased performance for the detection of bone metastasis and may be more efficient than PET/CT. However, more studies and research are required to understand the impact of PET/CT and MRI as diagnostic tools and how it impacts prostate cancer detection.
This Research Topic aims to provide an open discussion of how PET/CT and MRI impact the diagnosis of prostate cancer. We welcome Original Research, Reviews and Systematic Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Prostate cancer remains one of the most common cancers and is among the most lethal in men worldwide. It is significant that prostate cancer is identified in the early stages as the disease can be highly metastatic leading to a low survival rate. Therefore, it is essential for patients to have a better prognosis and able to be treated early. The diagnostic tools to identify prostate cancer have developed throughout the years which includes but is not limited to transrectal ultrasound-guided prostate biopsy and histopathology prior to radical prostatectomy. However, biopsies have been found to be invasive in addition to studies demonstrating an underdiagnosis of patients who have advanced prostate cancer.
Other diagnostic tools for prostate cancer include but are not limited to: pathological digital rectal examination (DRE), prostate specific antigen (PSA) and magnetic resonance image (MRI). These techniques are utilized to improve the detection of advanced prostate cancer in addition to reducing the invasive approach of biopsies. Addition to the current diagnostic tools, there is a development in 18F-fluoride (NaF) positron emission tomography/computed tomography (PET/CT) and 18F-fluorocholine (FCH) PET/CT, and whole-body magnetic resonance imaging (WBMRI) which has been proposed to detect prostate cancer metastasis. Studies have shown multi-parametric MRI has increased performance for the detection of bone metastasis and may be more efficient than PET/CT. However, more studies and research are required to understand the impact of PET/CT and MRI as diagnostic tools and how it impacts prostate cancer detection.
This Research Topic aims to provide an open discussion of how PET/CT and MRI impact the diagnosis of prostate cancer. We welcome Original Research, Reviews and Systematic Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
